Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication

İsmail Bayram

doi:10.55971/EJLS.1727347

Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication

Abstract

Parkinson's Disease is a progressive neurodegenerative disease affecting sensory-motor systems and decreasing patients' quality of life. This study aims to find a sophisticated method for detecting characteristics of patients and comparing gait, balance and tremors between the ON and OFF periods. The data provided by the Xsens (Movella) company belongs to 3 anonymous patients, and the content is unique for all 3 patients since they were unable to perform the same movement patterns due to different disease severity. Their descriptive information was not provided due to patient privacy. Tremor, gait and balance assessments were asked to be performed via preferred approaches and methods by using MVN Analyze Software. Kinematic improvements were detected in gait parameters such as cadence (step/min), the number of steps, speed (m/s), total distance (m), stride and length. The provided data shows that patients have some difficulties during turns and initiation of gait (freezing gait). It accompanies a delay in the first step at the beginning of the gait and after turns as well. For the tremor assessment, a heat map was generated based on the magnitude and frequency of the tremors. Both the magnitude and frequency of the tremors were smaller under the dopaminergic medication (ON: amplitude:4.99 cm frequency:4.04 Hz; OFF: amplitude:7.78 cm frequency:5.17 Hz). We were unable to assess the balance due to time limitations. Most of the parameters show an improvement in gait and tremors during the ON period. Results are important in terms of individualization of drug intake time and dosage.

Keywords

Supporting Institution

This study is partly funded by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) as part of Germany`s Excellence Strategy – EXC 2050/1 – Project ID 390696704 – Cluster of Excellence “Centre for Tactile Internet with Human-in-the-Loop” (CeTI) of Technische Universität Dresden.

Ethical Statement

Not applicable, because the data used in this article provided by the Xsens Company.

Thanks

This study has been orally presented at the 1st Movement & Training Sciences Congress held by Fenerbahçe University in İstanbul, TÜRKİYE. The author would like to express his sincere appreciation to the participants who volunteered for the study and Xsens Company for organizing this challenge. The author also extends his gratitude to Jonathan Lyon Jacob Lommen for his valuable support in the data analysis phase of the study, despite his decision not to be listed as a co-author due to his non-academic career interests.

References

World Health Organization (2022). Parkinson Disease: a Public Health Approach. Technical Brief. Retreived June 9, 2025 from https://www.who.int/publications/i/item/9789240050983
Silva S, Almeida AJ, Vale N. Importance of nanoparticles for the delivery of antiparkinsonian drugs. Pharmaceutics (2021);13:508. https://doi.org/10.3390/pharmaceutics13040508
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease. Jama (2014);311(16):1670-1683. https://doi.org/10.1001/jama.2014.3654
Malek N, Kanavou S, Lawton M, Pitz V, Grosset KA, Bajaj N, Barker RA, Ben‐Shlomo Y, Burn DJ, Foltynie T, Hardy J, Williams N, Wood N, Morris HR, Grosset DG. L-dopa responsiveness in early Parkinson’s disease is associated with the rate of motor progression. Park Relat Disord. (2019);65:55-61. https://doi.org/10.1016/j.parkreldis.2019.05.022
Prasad EM, Hung S. Current therapies in clinical trials of Parkinson’s disease: a 2021 update. Pharmaceuticals. (2021);14(8):717. https://doi.org/10.3390/ph14080717
Chen JJ, Lew M, Siderowf A. Treatment strategies and quality-of-care indicators for patients with Parkinson’s disease. J Manag Care Spec Pharm. (2009);15(3 Supp A):1-22. https://doi.org/10.18553/jmcp.2009.15.s3.1
Vorovenci RJ, Biundo R, Antonini A. Therapy-resistant symptoms in Parkinson’s disease. J Neural Transm. (2016);123,19-30. https://doi.org/10.1007/s00702-015-1463-8
Nonnekes J, Timmer MHM, Vries NM de, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson’s disease. J Mov Disord. (2016);31(11):1602-1609. https://doi.org/10.1002/mds.26712

Thomas I, Alam M, Bergquist F, Buvarp D, Memedi M, Nyholm D, Westin J. Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson’s disease: a first experience. J Neurol. (2019);266(3):651-658. https://doi.org/10.1007/s00415-019-09183-6
Khanna AJ, Adams J, Antoniades CA, Bloem BR, Carroll C, Cedarbaum JM, Cosman JD, Dexter DT, Dockendorf MF, Edgerton J, Gaetano L, Goikoetxea E, Hill D, Horak FB, Izmailova ES, Kangarloo T, Katabi D, Kopil C, Lindemann M, Mammen JR, Marek K, McFarthing K, Mirelman A, Müller MLTM, Pagano G, Peterschmitt M, Ren J, Rochester L, Sardar S, Siderowf A, Simuni T, Stephenson D, Swanson‐Fischer C, Wagner JA, Jones GB. Accelerating Parkinson’s disease drug development with federated learning approaches. npj Parkinsons Dis Nature Portfolio. (2024);10(1):225. https://doi.org/10.1038/s41531-024-00837-5
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. (2008);79(4):368-376. https://doi.org/10.1136/jnnp.2007.131045
Ertan H, Bayram İ. Fundamentals of human movement, its control and energetics. In Comparative Kinesiology of the Human Body. London: Elsevier; (2020). p. 29-45. ISBN: 978-0-12-812162-7
Altan E, Seide SE, Bayram İ, Gizzi L, Ertan H, Röhrle O. A systematic review and meta-analysis on the longitudinal effects of unilateral knee extension exercise on muscle strength. Front Sports Act Living. (2020);2:518148. https://doi.org/10.3389/fspor.2020.518148
Stephenson D, Alexander R, Aggarwal V, Badawy R, Bain LJ, Bhatnagar R, Bloem BR, Boroojerdi B, Burton J, Cedarbaum JM, Cosman JD, Dexter DT, Dockendorf MF, Dorsey ER, Dowling AV, Evers LJW, Fisher K, Frasier M, Garcia‐Gancedo L, Goldsack JC, Hill D, Hitchcock JM, Shulman J, Lawton MP, Lee SH, Lindemann M, Marek K, Mehrotra N, Meinders MJ, Minchik M, Oliva L, Romero K, Roussos G, Rubens R, Sadar S, Scheeren J, Sengoku E, Simuni T, Stebbins GT, Taylor KI, Yang B, Zach N. Precompetitive consensus building to facilitate the use of digital health technologies to support parkinson disease drug development through regulatory science. Digit Biomark. (2020);4(Suppl. 1):28–49. https://doi.org/10.1159/000512500
Titova N, Levin О, Кatunina Е, Chaudhuri КR. ‘Levodopa Phobia’: a review of a not uncommon and consequential phenomenon. npj Parkinsons Dis Nature Portfolio. (2018);4:31. https://doi.org/10.1038/s41531-018-0067-z
Rhyu HS, Rhi SY. The effects of training on different surfaces, on balance and gait performance in stroke hemiplegia. Rev Bras Med Esporte. (2021);27:592-596. https://doi.org/10.1590/1517-8692202127062020_0089
Fine AS, Kaufman ML, Goodman J, Turk BR, Bastian AJ, Lin D, Fatemi A, Keller J. Wearable sensors detect impaired gait and coordination in LBSL during remote assessments. Ann Clin Transl Neurol. (2022);9(4):468. https://doi.org/10.1002/acn3.51509
Pandis MFD, Tomino C, Proietti S, Rotondo R, Gaglione M, Casali M, Corbo M, Biase L di, Galli M, Goffredo M, Stocchi F. Mechanical peripheral stimulation for the treatment of gait disorders in patients with Parkinson’s disease: a multi-centre, double-blind, crossover randomized controlled trial. J NeuroEng Rehabil. (2025);22:77. https://doi.org/10.1186/s12984-025-01574-3
Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio RJ, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line—derived neurotrophic factor. J Neurosurg. (2005);102(2):216-222. https://doi.org/10.3171/jns.2005.102.2.0216
Mancini M, Afshari M, Almeida QJ, Huffmaster SLA, Balfany K, Camicioli R, Christiansen CL, Dale ML, Dibble LE, Earhart GM, Ellis TD, Griffith G, Hackney ME, Hopkins JO, Horak FB, Jones KE, Li L, O’Keefe JA, Kwei K, Olivier GN, Rao AK, Sivaramakrishnan A, Corcos DM. Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis. npj Parkinsons Dis Nature Portfolio. (2025);11:51. https://doi.org/10.1038/s41531-025-00897-1
Muñoz B, Valderrama J, Paredes JDA, Pino YJC, Navarro A, Orozco JL. Objective arm swing analysis in early-stage parkinson’s disease using an rgb-d camera (Kinect®)1. J Parkinsons Dis. (2018);8(4):563-570. https://doi.org/10.3233/jpd-181401
Pieterman M, Adams S, Jog M. Method of levodopa response calculation determines strength of association with clinical factors in Parkinson disease. Front Neurol. (2018);9:260. https://doi.org/10.3389/fneur.2018.00260
Radder DLM, Lima ALS de, Domingos J, Keus SHJ, Nimwegen M van, Bloem BR, Vries NM de. Physiotherapy in Parkinson’s disease: a meta-analysis of present treatment modalities. Neurorehabil Neural Repair. (2020);34(10):871-880. https://doi.org/10.1177/1545968320952799
Helmich RC, Bloem BR, Toni I. Motor imagery evokes increased somatosensory activity in parkinson’s disease patients with tremor. Hum Brain Mapp. (2012);33:1763-1779. https://doi.org/10.1002/hbm.21318
Palermo G, Giannoni S, Bellini G, Siciliano G, Ceravolo R. Dopamine transporter imaging, current status of a potential biomarker: A comprehensive review. Int J Mol Sci. (2021);22(20):11234. https://doi.org/10.3390/ijms222011234
Islam MdS, Rahman W, Abdelkader A, Lee S, Yang PT, Purks JL, Adams J, Schneider RB, Dorsey ER, Hoque E. Using AI to measure Parkinson’s disease severity at home. npj Digit Med. (2023);6:156. https://doi.org/10.1038/s41746-023-00905-9
Padilla-Godínez FJ, Ruiz-Ortega LI, Guerra‐Crespo M. Nanomedicine in the face of Parkinson’s disease: from drug delivery systems to nanozymes. Cells. (2022);11(21): 3445. https://doi.org/10.3390/cells11213445
Lawton M, Ben‐Shlomo Y, May M, Baig F, Barber TR, Klein J, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood N, Grosset DG, Shulman J. Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry. (2018);89:1279-1287. https://doi.org/10.1136/jnnp-2018-318337
Monge‐Fuentes V, Mayer AB, Lima MR, Geraldes LR, Zanotto LN, Moreira KG, Martins OP, Piva HL, Felipe MSS, Amaral AC, Bocca AL, Tedesco AC, Mortari MR. Dopamine-loaded nanoparticle systems circumvent the blood–brain barrier restoring motor function in mouse model for Parkinson’s Disease. Sci Rep. (2021);11:15185. https://doi.org/10.1038/s41598-021-94175-8
Grétarsdóttir HM, Widman E, Johansson A, Nyholm D. Personalized medicine approach in treating parkinson’s disease, using oral administration of levodopa/carbidopa microtablets in clinical practice. J Pers Med. (2021);11(8):720. https://doi.org/10.3390/jpm11080720
He X, Mo C, Zhang Y, Cai Y, Yang X, Qian Y, Xiao Q. Effect of acute levodopa up-titration on blood pressure in patients with early stage Parkinson’s disease: results of a levodopa challenge test. Front Aging Neurosci. (2022);13:778856. https://doi.org/10.3389/fnagi.2021.778856
Catalán MJ, Antonini A, Calopa M, Băjenaru O, Fábregues O de, Mínguez‐Castellanos A, Odin P, García-Moreno JM, Pedersen SW, Pirtošek Z, Kulisevsky J. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? eNeurologicalSci. (2017);8:44-53. https://doi.org/10.1016/j.ensci.2017.06.004
Laar T van, Chaudhuri КR, Antonini A, Henriksen T, Trošt M. Infusion therapies in the treatment of Parkinson’s disease. J Parkinsons Dis. (2023);13(5):641-657. https://doi.org/10.3233/jpd-225112
Kalia LV, Lang AE. Parkinson’s disease. The Lancet. (2015);386(9996):896-912. https://doi.org/10.1016/s0140-6736(14)61393-3
Georgy EE, Barsnley S, Chellappa R. Effect of physical exercise-movement strategies programme on mobility, falls, and quality of life in Parkinson’s disease. Int J Ther Rehabil. (2012);19(2):88-96. https://doi.org/10.12968/ijtr.2012.19.2.88

Details

Primary Language

English

Subjects

Biomechanics in Sports Science

Journal Section

Research Article

Authors

İsmail Bayram ^*
0000-0003-0685-6152
Germany

Publication Date

August 31, 2025

Submission Date

June 25, 2025

Acceptance Date

August 17, 2025

Published in Issue

Year 2025 Volume: 4 Number: 2

DOI

https://doi.org/10.55971/EJLS.1727347

IZ

https://izlik.org/JA83XK95SH

Cite

RIS / Bibtex

APA

Bayram, İ. (2025). Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication. European Journal of Life Sciences, 4(2), 84-93. https://doi.org/10.55971/EJLS.1727347

AMA

1.Bayram İ. Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication. Eur J Life Sci. 2025;4(2):84-93. doi:10.55971/EJLS.1727347

Chicago

Bayram, İsmail. 2025. “Evaluation of Functional Movement Parameters of Parkinson`s Patients During ON and OFF States of Dopaminergic Medication”. European Journal of Life Sciences 4 (2): 84-93. https://doi.org/10.55971/EJLS.1727347.

EndNote

Bayram İ (August 1, 2025) Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication. European Journal of Life Sciences 4 2 84–93.

IEEE

[1]İ. Bayram, “Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication”, Eur J Life Sci, vol. 4, no. 2, pp. 84–93, Aug. 2025, doi: 10.55971/EJLS.1727347.

ISNAD

Bayram, İsmail. “Evaluation of Functional Movement Parameters of Parkinson`s Patients During ON and OFF States of Dopaminergic Medication”. European Journal of Life Sciences 4/2 (August 1, 2025): 84-93. https://doi.org/10.55971/EJLS.1727347.

JAMA

1.Bayram İ. Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication. Eur J Life Sci. 2025;4:84–93.

MLA

Bayram, İsmail. “Evaluation of Functional Movement Parameters of Parkinson`s Patients During ON and OFF States of Dopaminergic Medication”. European Journal of Life Sciences, vol. 4, no. 2, Aug. 2025, pp. 84-93, doi:10.55971/EJLS.1727347.

Vancouver

1.İsmail Bayram. Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication. Eur J Life Sci. 2025 Aug. 1;4(2):84-93. doi:10.55971/EJLS.1727347